Aethlon Medical Inc (AEMD)
NASDAQ:AEMD
Want to see AEMD full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026After Close (Confirmed)
Period Ending
2027 (Q1)Consensus EPS Forecast
-0.79Last Year’s EPS
-8.5Same Quarter Last Year
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated multiple operational and clinical progress points — completion of Cohort 2 with DSMB clearance, initiation of Cohort 3 with a successful first treatment, expansion of preclinical EV research into rheumatoid arthritis and chronic kidney disease, successful compatibility testing with a simplified blood pump, disciplined cost reductions (operating expenses down 21.9%), and an improved net loss (~46% reduction). However, material challenges remain: cash at fiscal year‑end was modest (~$5.0M) despite a subsequent ~$1.85M ATM raise, the company remains unprofitable (net loss $7.2M), the current oncology study is small and not powered for efficacy, and there is no near‑term commercial revenue or explicit commercialization timeline. Overall, operational and clinical execution trends are positive but balanced by funding and development‑stage risks.Company Guidance
Completed Cohort 2 and Progressed to Cohort 3 in Australian Oncology Trial
Enrollment and treatment in Cohort 2 completed (3 participants received two 4-hour Hemopurifier treatments each). An independent DSMB identified no safety concerns and recommended advancing to Cohort 3 without protocol modifications. The first participant in Cohort 3 has been treated (three Hemopurifier sessions) with no device deficiencies and is in safety follow-up; screening is active at all three sites.
Clinical Biomarker and Measurement Data Collected
Central lab at the University of Sydney measured extracellular vesicle (EV) and T cell parameters for Cohort 2; formal statistical analyses comparing three dosing regimens will be performed by the CRO at trial completion. Prior cohort data showed reductions in EVs (including PDL1+ EVs) and positive T cell signals.
Preclinical Pipeline Expansion — EV Research in New Indications
Advancing preclinical studies evaluating removal of extracellular vesicles from plasma samples in rheumatoid arthritis and chronic kidney disease (platelet-derived EVs implicated in RA; EVs linked to heart failure in CKD). Work is being conducted in-house and intended to support abstracts and peer-reviewed publications.
Compatibility with Simplified Blood Pump Demonstrated
Initial testing of Hemopurifier compatibility with Sabre Medical’s simplified blood pump showed successful flow rates and fluid transfer. This could enable treatment outside dialysis units, use of less invasive vascular access, and broader physician and site adoption.
Compassionate Use Ebola Protocol Remains Open
The compassionate use protocol for life‑threatening viral infections (Ebola-specific) remains open for enrollment (up to 20 subjects at up to 10 U.S. institutions). Company has shared in vitro and clinical removal data with WHO and U.S. special pathogen centers.
Improved Expense Discipline — Operating Expenses Down 21.9% Year‑over‑Year
Consolidated operating expenses declined 21.9% YoY to approximately $7.3 million in FY2026 from $9.3 million in FY2025, driven by reductions of ~$1.1M in payroll, ~$0.5M in G&A, and ~$0.4M in professional fees.
Stronger Post‑Year‑End Liquidity and Improved Net Loss
Cash and cash equivalents were approximately $5.0 million as of March 31, 2026, and the company raised approximately $1.85 million in net proceeds afterward via an at‑the‑market (ATM) program. Net loss attributable to common stockholders improved to $7.2 million (FY2026) from $13.4 million (FY2025) — a ~46% reduction.
Other Income Improved Versus Prior Year
Other income in FY2026 was approximately $142,000 (primarily interest income) versus other expense of ~ $4 million in FY2025; the prior year included approximately $4.7M of noncash financing-related charges.
AEMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AEMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jun 10, 2026 | $2.02 | $1.90 | -5.94% |
Feb 12, 2026 | $1.98 | $1.96 | -1.01% |
Nov 12, 2025 | $4.20 | $4.74 | +12.86% |
Aug 13, 2025 | $12.30 | $11.70 | -4.88% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Aethlon Medical Inc (AEMD) report earnings?
Aethlon Medical Inc (AEMD) is schdueled to report earning on Aug 12, 2026, After Close (Confirmed).
What is Aethlon Medical Inc (AEMD) earnings time?
Aethlon Medical Inc (AEMD) earnings time is at Aug 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AEMD EPS forecast?
AEMD EPS forecast for the fiscal quarter 2027 (Q1) is -0.79.